Charles River Laboratories International, Inc. Stock
Equities
CRL
US1598641074
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
218.7 USD | -0.14% | -3.57% | -8.32% |
Financials (USD)
Sales 2024 * | 4.22B | Sales 2025 * | 4.53B | Capitalization | 11.28B |
---|---|---|---|---|---|
Net income 2024 * | 406M | Net income 2025 * | 513M | EV / Sales 2024 * | 3.13 x |
Net Debt 2024 * | 1.94B | Net Debt 2025 * | 1.46B | EV / Sales 2025 * | 2.81 x |
P/E ratio 2024 * |
27.7
x | P/E ratio 2025 * |
22.4
x | Employees | 21,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.93% |
Latest transcript on Charles River Laboratories International, Inc.
1 day | -1.12% | ||
1 week | -5.83% | ||
Current month | -4.37% | ||
1 month | -5.83% | ||
3 months | -11.30% | ||
6 months | +12.34% | ||
Current year | -7.36% |
Managers | Title | Age | Since |
---|---|---|---|
James Foster
CEO | Chief Executive Officer | 73 | 75-12-31 |
Flavia Pease
DFI | Director of Finance/CFO | 51 | 22-04-24 |
Birgit Girshick
COO | Chief Operating Officer | 54 | 89-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
George Massaro
BRD | Director/Board Member | 76 | 02-12-31 |
Virginia Wilson
BRD | Director/Board Member | 68 | 19-09-30 |
Robert Bertolini
BRD | Director/Board Member | 61 | 11-01-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.05% | 1 M€ | 0.00% | - | |
2.07% | 5 M€ | -1.80% | - | |
1.08% | 0 M€ | 0.00% | - | |
0.98% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 217.4 | -0.71% | 6 403 |
24-05-22 | 219 | -1.12% | 360,257 |
24-05-21 | 221.5 | -0.71% | 375,305 |
24-05-20 | 223.1 | +0.65% | 473,731 |
24-05-17 | 221.6 | -1.40% | 927,644 |
Delayed Quote Nyse, May 22, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.36% | 11.28B | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+44.87% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |
- Stock Market
- Equities
- CRL Stock